Cell therapy for Parkinson’s disease: II. Somatic stem cell-based applications-

Adv G erontol. 2009; 22(1) : 150-66. Cell therapy for Parkinson’s disease: II. Somatic stem cell-based applications- [Article in Russian] Anisimov SV. Abstract Motor dysfunctions in Parkinson’s disease are believed to be primarily due to the degeneration of dopaminergic neurons located in the substantia nigra pars compacta. Numerous cell replacement therapy approaches have been developed…

Cell therapy for Parkinson’s disease: II. Somatic stem cell-based applications-

Stem Cells Dev. 2010 Jul; 19(7) : 1017-23. Cell therapy for Parkinson’s disease: II. Somatic stem cell-based applications- Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. Farber Institute for Neurosciences, Department of Neurology, Thomas Jefferson University , Philadelphia, PA 19107, USA. Abstract Cell replacement therapy could be an important treatment strategy…

Transplantation of retinoic acid treated murine embryonic stem cells & behavioural deficit in Parkinsonian rats.

Indian J Med Res. 2010 Apr; 131 : 536-44. Transplantation of retinoic acid treated murine embryonic stem cells & behavioural deficit in Parkinsonian rats. Fathi F, Altiraihi T, Mowla SJ, Movahedin M. Kurdistan Center for Cellular & Molecular Research, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj,Tarbiat Modarres University, Tehran, Iran. farfath@yahoo.com Abstract BACKGROUND…

Stem cell & brain repair in Parkinson’s disease

Regen Med. 2010 Mar; 5(2) : 267-78. Stem cell-derived dopamine neurons for brain repair in Parkinson’s disease. Fricker-Gates RA, Gates MA. Keele University, Keele, Staffordshire, UK. r.a.fricker-gates@hfac.keele.ac.uk Abstract One of the prospects for a curative treatment for Parkinson’s disease is to replace the lost dopaminergic neurons. Preclinical and clinical trials have demonstrated that dissected fetal…

Parkinson’s disease and related disorders

IDrugs. 2010 Feb; 13(2) : 82-4. Parkinson’s disease and related disorders–XVIII WFN World Congress. Grosset D. Southern General Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK. d.grosset@clinmed.gla.ac.uk Abstract The XVIII World Federation of Neurology (WFN) World Congress on Parkinson’s Disease and Related Disorders, held in Miami, FL, USA, included topics covering new therapeutic developments in…

Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery.

Curr Med Chem. 2010; 17(8) : 759-66. Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A. Center of Physiology and Pathophysiology, Institute of Neurophysiology, and Center of Molecular Medicine, University of Cologne (CMMC), Robert-Koch Str. 39, Cologne, Germany. Abstract Human…

Human ES and iPS cells as cell sources for the treatment of Parkinson’s disease: current state and problems.

J Cell Biochem. 2010 Feb 1; 109(2) : 292-301. Human ES and iPS cells as cell sources for the treatment of Parkinson’s disease: current state and problems. Hwang DY, Kim DS, Kim DW. Stem Cell Research Center, 21C Frontier R&D Program of Ministry of Education, Science and Technology, Yonsei University Medical Center, Seoul, South Korea.…

Stem cells in human neurodegenerative disorders

J Clin Invest. 2010 Jan 4; 120(1): 29-40. doi: 10.1172/JCI40543. Stem cells in human neurodegenerative disorders–time for clinical translation? Lindvall O, Kokaia Z. Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden. olle.lindvall@med.lu.se Abstract Stem cell-based approaches have received much hype as potential treatments for neurodegenerative disorders. Indeed, transplantation of stem…